Key facts
- It has raised $12.3M across 2 recorded rounds; the latest was Seed Round ($1.7M) in Feb 2025.
- Notable investors include Creative Destruction Lab, Desjardins Capital, YSpace (Toronto), CABHI, Life Sciences BC — 24 tracked in total.
- VoxCell BioInnovation has filed 2 Form Ds with the SEC since 2024, most recently Mar 2025 ($1.7M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for VoxCell BioInnovation
Funding rounds
2 roundsAbout VoxCell BioInnovation
Developer of 3D (three-dimensional) bioprinted human tissue models designed to enhance drug development and testing accuracy. The company offers vascularized, physiologically relevant tissue constructs that replicate human biology, enabling pharmaceutical researchers and drug developers to predict clinical outcomes and accelerate therapeutic discovery.
- Sector
- Healthcare
- HQ
- Victoria, Canada
- Founded
- 2020
- Employees
- 27
- Website
- voxcell.com/
- Ownership
- Privately Held (backing)
VoxCell BioInnovation doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VoxCell BioInnovation shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VoxCell BioInnovation in its N-PORT filings yet. We sweep new filings monthly.